department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Spravato · pharmadog

pharmadog
drugs
Spravato

drug

patient view →

esketamine hydrochloride

Marketedupdated 2mo ago

by Johnson & Johnson Innovative Medicine

Approved

annual revenue · 2024–2024peak $1.0B

community read0 votes

indications

investigational

Major Depression

all catalysts(1)

phase 1 initiation · 1

News(0)

no news has mentioned this drug yet

brand

Spravato

generic

esketamine hydrochloride

indication

Major Depressive Disorder

phase

marketed

approved

2019-03-05

phase 1 initiation

Chiral Biotech Pharma Pty Ltd — esketamine hydrochloride (Phase I Trial Initiation)

esketamine hydrochloride

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 20, 2027

256 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (7)

Feb 18, 2040method-of-use (U-3813)US 11883526
Sep 10, 2035method-of-use (U-3036)US 10869844
Sep 10, 2035method-of-use (U-3257)US 11173134
Sep 10, 2035method-of-use (U-3035)US 11311500
Mar 14, 2034method-of-use (U-3446)US 11446260
Mar 5, 2033method-of-use (U-4112)US 8785500
Mar 20, 2027method-of-use (U-4112)US 9592207256d

FDA exclusivities (1)

Jan 17, 2028I-959Indication (3y)1.5y

🐶 often sniffed alongside

top 5

tagApproval68 co-mentions · 17 sources
drugesketamine35 co-mentions · 18 sources
drugSRX-2535 co-mentions · 18 sources
companyChiral Biotech Pharma Pty Ltd1 co-mentions · 1 sources
tagMajor Depression1 co-mentions · 1 sources

Trials studying esketamine hydrochloride

phase4Positioning of Esketamine Treatment in the Real-world Management of Depressionrecruitingn=162